Testosterone

Generic Name: Testosterone

Brand Names: Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₂

CAS Number: 58-22-0

Unique Ingredient Identifier: 3XMK78S47O

Background: Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication: Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

Puberty, Testosterone, and Brain Development

Recruiting

Conditions: Gender Identity
Gender Dysphoria in Adolescents and Adults
Headache
Transgender

Interventions: Drug: Testosterone

First Posted Date: 2024-11-01

Last Posted Date: 2024-12-18

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 100

Registration Number: NCT06670053

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

Recruiting

Conditions: Hypogonadism
Gender Identity Dysphoria

Interventions: Drug: Fortesta
Drug: Estradiol

First Posted Date: 2024-02-07

Last Posted Date: 2024-02-07

Lead Sponsor: Walter Reed National Military Medical Center

Target Recruit Count: 75

Registration Number: NCT06247267

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Factors Associated With the Acne Severity Among Transmen Population: a Cross-sectional Study

Completed

Conditions: Acne
Transgenderism

First Posted Date: 2023-11-28

Last Posted Date: 2023-11-28

Lead Sponsor: Mahidol University

Target Recruit Count: 247

Registration Number: NCT06149065

Locations: 🇹🇭
Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Ratchathewi, Bangkok, Thailand

The Influence of Testosterone on Experimental Pain Perception

Early Phase 1

Completed

Conditions: Acute Pain

Interventions: Drug: Testosterone
Other: Placebo Syrup

First Posted Date: 2023-03-23

Last Posted Date: 2024-08-05

Lead Sponsor: University of New Mexico

Target Recruit Count: 20

Registration Number: NCT05781685

Locations: 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men

Not yet recruiting

Conditions: Testosterone Deficiency
Metabolic Disturbance
Cardiovascular Diseases
Diabetes
Hypogonadism, Male
Androgen Deficiency
Metabolic Disease
Obesity
NAFLD
Prostate Cancer

Interventions: Drug: Testosterone
Drug: GnRH

First Posted Date: 2023-03-17

Last Posted Date: 2023-03-17

Lead Sponsor: Royal College of Surgeons, Ireland

Target Recruit Count: 60

Registration Number: NCT05773183

Locations: 🇮🇪
Beaumont Hospital, Dublin 9, Ireland

Perioperative Testosterone Replacement Therapy in Sarcopenic Male Colorectal Cancer Patients

Conditions: Perioperative Care
Colorectal Cancer
Testosterone Replacement Therapy
Sarcopenia
Hypogonadism, Male

First Posted Date: 2022-05-10

Last Posted Date: 2022-05-10

Lead Sponsor: London North West Healthcare NHS Trust

Target Recruit Count: 30

Registration Number: NCT05367284

Locations: 🇬🇧
London North West University Healthcare NHS Trust, London, United Kingdom

Testosterone & Tamoxifen Trial

Not Applicable

Terminated

Conditions: Male Breast Cancer

Interventions: Drug: AndroGel

First Posted Date: 2021-12-14

Last Posted Date: 2024-08-09

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 5

Registration Number: NCT05156606

Locations: 🇳🇱
UMCG, Groningen, Netherlands

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

Phase 4

Conditions: Hypogonadism

Interventions: Drug: Natesto

First Posted Date: 2021-07-26

Last Posted Date: 2022-07-06

Lead Sponsor: Acerus Pharmaceuticals Corporation

Target Recruit Count: 218

Registration Number: NCT04976595

Locations: 🇺🇸
Eclipse Clinical Research, Tucson, Arizona, United States
🇺🇸
Preferred Research Partners, Little Rock, Arkansas, United States
🇺🇸
NYU Langone Health, New York, New York, United States

and more 27 locations

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

Phase 4

Recruiting

Conditions: Long QT Syndrome
Abnormalities, Drug-Induced

Interventions: Drug: Progesterone
Drug: Ibutilide
Drug: Placebo
Drug: Testosterone

First Posted Date: 2020-12-19

Last Posted Date: 2024-06-03

Lead Sponsor: Indiana University

Target Recruit Count: 83

Registration Number: NCT04675788

Locations: 🇺🇸
Indiana Clinical Research Center, Indianapolis, Indiana, United States
🇺🇸
Purdue University, Indianapolis, Indiana, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

Vogelxo(R) ABPM Study in Hypogandal Men

Phase 4

Completed

Conditions: Hypogonadism, Male

Interventions: Drug: Vogelxo

First Posted Date: 2020-09-22

Last Posted Date: 2024-10-18

Lead Sponsor: Upsher-Smith Laboratories

Target Recruit Count: 122

Registration Number: NCT04558567

Locations: 🇺🇸
Upsher-Smith Clinical Trial Site #1, Miami, Florida, United States
🇺🇸
Upsher-Smith Clinical Trials Site #8, San Antonio, Texas, United States
🇺🇸
Upsher-Smith Clinical Trial Site #2, Anaheim, California, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy